Photodynamic therapy alone versus combined with intravitreal bevacizumab for neovascular age-related macular degeneration without polypoidal choroidal vasculopathy in Japanese patients

  • Ryuhei Hara
  • Takahiro Kawaji
  • Yasuya Inomata
  • Jin Tahara
  • Nina Sagara
  • Mikiko Fukushima
  • Hidenobu Tanihara
Retinal Disorders
  • 142 Downloads

Abstract

Background

To compare 12-month results of two single initial treatments—photodynamic therapy with verteporfin alone (PDT group), and this therapy combined with intravitreal bevacizumab (IVB) (COMB group)—for neovascular age-related macular degeneration (AMD), not including patients with polypoidal choroidal vasculopathy (PCV) who were presumed to have AMD.

Methods

This retrospective study evaluated 23 eyes in the PDT group and 22 eyes in the COMB group. IVB (1.25 mg) was administered within 2 weeks after PDT. Main outcome measures were best-corrected visual acuity (VA), central foveal thickness by optical coherence tomography, and number of treatments.

Results

At month 12, the PDT group had gained 0.7 letter mean VA and the COMB group, 8.8 letters (P = 0.04). Ten eyes (43%) in the PDT group and 19 eyes (86%) in the COMB group received only one treatment, and significant difference was found (P = 0.005). No severe ocular or systemic safety concerns were discovered.

Conclusions

Our 12-month results of PDT combined with IVB for Japanese patients with AMD without PCV appeared to be more effective than those of PDT alone with fewer treatments.

Keywords

Age-related macular degeneration Bevacizumab Combined therapy Japanese patients Photodynamic therapy Polypoidal choroidal vasculopathy 

References

  1. 1.
    Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (1999) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials—TAP report. Arch Ophthalmol 117:1329–1345Google Scholar
  2. 2.
    Bressler NM, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials—TAP report 2. Arch Ophthalmol 119:198–207PubMedGoogle Scholar
  3. 3.
    Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group (2002) Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition’s impact on vision outcomes—TAP report No. 3. Arch Ophthalmol 120:1443–1454Google Scholar
  4. 4.
    Japanese Age-Related Macular Degeneration Trial Study Group (2003) Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol 136:1049–1061CrossRefGoogle Scholar
  5. 5.
    Yannuzzi LA, Wong DW, Sforzolini BS, Goldbaum M, Tang KC, Spaide RF, Freund KB, Slakter JS, Guyer DR, Sorenson JA, Fisher Y, Maberley D, Orlock DA (1999) Polypoidal choroidal vasculopathy and neovascularized age-related macular degeneration. Arch Ophthalmol 117:1503–1510PubMedGoogle Scholar
  6. 6.
    Ciardella AP, Donsoff IM, Huang SJ, Costa DL, Yannuzzi LA (2004) Polypoidal choroidal vasculopathy. Surv Ophthalmol 49:25–37CrossRefPubMedGoogle Scholar
  7. 7.
    Sho K, Takahashi K, Yamada H, Wada M, Nagai Y, Otsuji T, Nishikawa M, Mitsuma Y, Yamazaki Y, Matsumura M, Uyama M (2003) Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics. Arch Ophthalmol 121:1392–1396CrossRefPubMedGoogle Scholar
  8. 8.
    Obata R, Yanagi Y, Kami J, Takahashi H, Inoue Y, Tamaki Y (2006) Polypoidal choroidal vasculopathy and retinochoroidal anastomosis in Japanese patients eligible for photodynamic therapy for exudative age-related macular degeneration. Jpn J Ophthalmol 50:354–360CrossRefPubMedGoogle Scholar
  9. 9.
    Spaide RF, Donsoff I, Lam DL, Yannuzzi LA, Jampol LM, Slakter J, Sorenson J, Freund KB (2002) Treatment of polypoidal choroidal vasculopathy with photodynamic therapy. Retina 22:529–535CrossRefPubMedGoogle Scholar
  10. 10.
    Chan WM, Lam DS, Lai TY, Liu DT, Li KK, Yao Y, Wong TH (2004) Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy. One-year results of a prospective case series Ophthalmology 111:1576–1584Google Scholar
  11. 11.
    Ogino T, Takeda M, Imaizumi H, Okushiba U (2007) Photodynamic therapy for age-related macular degeneration in Japanese patients: results after one year. Jpn J Ophthalmol 51:210–215CrossRefPubMedGoogle Scholar
  12. 12.
    Gomi F, Ohji M, Sayanagi K, Sawa M, Sakaguchi H, Oshima Y, Ikuno Y, Tano Y (2008) One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology 115:141–146CrossRefPubMedGoogle Scholar
  13. 13.
    Tano Y, Ophthalmic PDT Study Group (2008) Guidelines for PDT in Japan. Ophthalmology 115:585.e6–585.e6CrossRefGoogle Scholar
  14. 14.
    Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA Study Group (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431CrossRefPubMedGoogle Scholar
  15. 15.
    Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, ANCHOR Study Group (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432–1444CrossRefPubMedGoogle Scholar
  16. 16.
    Novack GD (2008) Pharmacotherapy for the treatment of choroidal neovascularization due to age-related macular degeneration. Annu Rev Pharmacol Toxicol 48:61–78CrossRefPubMedGoogle Scholar
  17. 17.
    Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N (2008) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 145:239–248CrossRefPubMedGoogle Scholar
  18. 18.
    Zarbin MA (2004) Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 122:598–614CrossRefPubMedGoogle Scholar
  19. 19.
    Lazic R, Gabric N (2007) Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 245:68–73CrossRefPubMedGoogle Scholar
  20. 20.
    Gomi F, Sawa M, Sakaguchi H, Tsujikawa M, Oshima Y, Kamei M, Tano Y (2008) Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol 92:70–73CrossRefPubMedGoogle Scholar
  21. 21.
    Lai TY, Chan WM, Liu DT, Luk FO, Lam DS (2008) Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. Br J Ophthalmol 92:661–666CrossRefPubMedGoogle Scholar
  22. 22.
    Gelisken F, Lafaut BA, Inhoffen W, Voelker M, Grisanti S, Bartz-Schmidt KU (2004) Clinicopathological findings of choroidal neovascularisation following verteporfin photodynamic therapy. Br J Ophthalmol 88:207–211CrossRefPubMedGoogle Scholar
  23. 23.
    Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GO (2003) Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 44:4473–4480CrossRefPubMedGoogle Scholar
  24. 24.
    Spaide RF, Sorenson J, Maranan L (2005) Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 112:301–304CrossRefPubMedGoogle Scholar
  25. 25.
    Weigert G, Michels S, Sacu S, Varga A, Prager F, Geitzenauer W, Schmidt-Erfurth U (2008) Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. Br J Ophthalmol 92:356–360CrossRefPubMedGoogle Scholar
  26. 26.
    Gillies MC, Kuzniarz M, Craig J, Ball M, Luo W, Simpson JM (2005) Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology 112:139–143CrossRefPubMedGoogle Scholar
  27. 27.
    Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, Noureddin BN (2008) Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol 145:249–256CrossRefPubMedGoogle Scholar
  28. 28.
    Kaiser PK, Blodi BA, Shapiro H, Acharya NR, MARINA Study Group (2007) Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 114:1868–1875CrossRefPubMedGoogle Scholar
  29. 29.
    Heier JS, Boyer DS, Ciulla TA, Ferrone PJ, Jumper JM, Gentile RC, Kotlovker D, Chung CY, Kim RY, FOCUS Study Group (2006) Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 124:1532–1542CrossRefPubMedGoogle Scholar
  30. 30.
    Antoszyk AN, Tuomi L, Chung CY, Singh A, FOCUS Study Group (2008) Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 145:862–874CrossRefPubMedGoogle Scholar
  31. 31.
    Wolf S, PROTECT Study Group (2007) Nine month exploratory endpoint results from an open-label, multicenter, phase II study of same-day verteporfin and ranibizumab 0.5 mg (PROTECT Study), as measured using optical coherence tomography (OCT), fundus photography and fluorescein angiography (FA). Invest Ophthalmol Vis Sci 48:E-Abstract 2871Google Scholar
  32. 32.
    Smith BT, Dhalla MS, Shah GK, Blinder KJ, Ryan EH Jr, Mittra RA (2008) Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration. Retina 28:675–681CrossRefPubMedGoogle Scholar
  33. 33.
    Lazic R, Gabric N (2007) Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 114:1179–1185CrossRefPubMedGoogle Scholar
  34. 34.
    Kaiser PK, Registry of Visudyne AMD Therapy Writing Committee (2009) Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmology 116:747–755CrossRefPubMedGoogle Scholar
  35. 35.
    Visudyne in Minimally Classic Choroidal Neovascularization Study Group (2005) Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 123:448–457CrossRefGoogle Scholar
  36. 36.
    Costagliola C, Romano MR, Rinaldi M, Dell’omo R, Chiosi F, Menzione M, Semeraro F (2009) Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age related macular degeneration. Br J Ophthalmol. doi:10.1136/bjo.2009.159343 PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Ryuhei Hara
    • 1
  • Takahiro Kawaji
    • 1
  • Yasuya Inomata
    • 1
  • Jin Tahara
    • 1
  • Nina Sagara
    • 1
  • Mikiko Fukushima
    • 1
  • Hidenobu Tanihara
    • 1
  1. 1.Department of Ophthalmology and Visual Science, Graduate School of Medical SciencesKumamoto UniversityKumamotoJapan

Personalised recommendations